Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Friday, December 28, 2018

Deep convolutional neural network (DCNN) models to improve the diagnostic accuracy of thyroid cancer by analysing sonographic imaging data from clinical ultrasounds

https://www.ncbi.nlm.nih.gov/pubmed/30583848

Lancet Oncol. 2018 Dec 21. pii: S1470-2045(18)30762-9. doi: 10.1016/S1470-2045(18)30762-9. [Epub ahead of print]

Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study.

Li X1Zhang S2Zhang Q3Wei X2Pan Y4Zhao J2Xin X2Qin C5Wang X2Li J6Yang F2Zhao Y7Yang M8Wang Q8Zheng Z9Zheng X9Yang X10Whitlow CT11Gurcan MN12Zhang L3Wang X3Pasche BC13Gao M14Zhang W13Chen K15.

Author information

1
Tianjin Cancer Institute, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
2
Department of Diagnostic and Therapeutic Ultrasonography, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
3
Department of Maxillofacial and Otorhinolaryngology Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
4
Department of Pathology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
5
Department of Thyroid and Breast Surgery, Weihai Municipal Hospital, Shandong, China.
6
Department of Ultrasonography, Weihai Municipal Hospital, Shandong, China.
7
Department of Ultrasonography, Affiliated Hospital of Chifeng University, Inner Mongolia, China.
8
Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
9
Department of Ultrasonography, Integrated Traditional Chinese and Western Medicine Hospital, Jilin, China.
10
Department of Ultrasonography, Dezhou Municiple Hospital, Shandong, China.
11
Departments of Radiology and Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, USA.
12
Center for Biomedical Informatics Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
13
Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
14
Department of Thyroid and Neck Cancer, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
15
Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China. Electronic address: chenkexin@tjmuch.com.

Abstract

BACKGROUND:

The incidence of thyroid cancer is rising steadily because of overdiagnosis and overtreatment conferred by widespread use of sensitive imaging techniques for screening. This overall incidence growth is especially driven by increased diagnosis of indolent and well-differentiated papillary subtype and early-stage thyroid cancer, whereas the incidence of advanced-stage thyroid cancer has increased marginally. Thyroid ultrasound is frequently used to diagnose thyroid cancer. The aim of this study was to use deep convolutional neural network (DCNN) models to improve the diagnostic accuracy of thyroid cancer by analysing sonographic imaging data from clinical ultrasounds.

METHODS:

We did a retrospective, multicohort, diagnostic study using ultrasound images sets from three hospitals in China. We developed and trained the DCNN model on the training set, 131 731 ultrasound images from 17 627 patients with thyroid cancer and 180 668 images from 25 325 controls from the thyroid imaging database at Tianjin Cancer Hospital. Clinical diagnosis of the training set was made by 16 radiologists from Tianjin Cancer Hospital. Images from anatomical sites that were judged as not having cancer were excluded from the training set and only individuals with suspected thyroid cancer underwent pathological examination to confirm diagnosis. The model's diagnostic performance was validated in an internal validation set from Tianjin Cancer Hospital (8606 images from 1118 patients) and two external datasets in China (the Integrated Traditional Chinese and Western Medicine Hospital, Jilin, 741 images from 154 patients; and the Weihai Municipal Hospital, Shandong, 11 039 images from 1420 patients). All individuals with suspected thyroid cancer after clinical examination in the validation sets had pathological examination. We also compared the specificity and sensitivity of the DCNN model with the performance of six skilled thyroid ultrasound radiologists on the three validation sets.

FINDINGS:

Between Jan 1, 2012, and March 28, 2018, ultrasound images for the four study cohorts were obtained. The model achieved high performance in identifying thyroid cancer patients in the validation sets tested, with area under the curve values of 0·947 (95% CI 0·935-0·959) for the Tianjin internal validation set, 0·912 (95% CI 0·865-0·958) for the Jilin external validation set, and 0·908 (95% CI 0·891-0·925) for the Weihai external validation set. The DCNN model also showed improved performance in identifying thyroid cancer patients versus skilled radiologists. For the Tianjin internal validation set, sensitivity was 93·4% (95% CI 89·6-96·1) versus 96·9% (93·9-98·6; p=0·003) and specificity was 86·1% (81·1-90·2) versus 59·4% (53·0-65·6; p<0·0001). For the Jilin external validation set, sensitivity was 84·3% (95% CI 73·6-91·9) versus 92·9% (84·1-97·6; p=0·048) and specificity was 86·9% (95% CI 77·8-93·3) versus 57·1% (45·9-67·9; p<0·0001). For the Weihai external validation set, sensitivity was 84·7% (95% CI 77·0-90·7) versus 89·0% (81·9-94·0; p=0·25) and specificity was 87·8% (95% CI 81·6-92·5) versus 68·6% (60·7-75·8; p<0·0001).

INTERPRETATION:

The DCNN model showed similar sensitivity and improved specificity in identifying patients with thyroid cancer compared with a group of skilled radiologists. The improved technical performance of the DCNN model warrants further investigation as part of randomised clinical trials.

FUNDING:

The Program for Changjiang Scholars and Innovative Research Team in University in China, and National Natural Science Foundation of China.

PMID:
 
30583848
 
DOI:
 
10.1016/S1470-2045(18)30762-9

Major vessel invasion by thyroid cancer

https://www.ncbi.nlm.nih.gov/pubmed/30580637

Expert Rev Anticancer Ther. 2018 Dec 24:1-13. doi: 10.1080/14737140.2019.1559059. [Epub ahead of print]

Major vessel invasion by thyroid cancer: a comprehensive review.

Author information

1
a Department of Surgery , St. Paul's Hospital & University of British Columbia , Vancouver , British Columbia , Canada.

Abstract

Gross extrathyroidal extension of thyroid cancer is an indicator of a worse cancer prognosis and may lead to major vessel invasion (MVI) that represents an uncommon and highly morbid manifestation of disease progression. Areas covered: This review aims to evaluate the current literature reporting on thyroid cancer that exhibits MVI, with a focus on relevant patient and pathological characteristics, diagnostic evaluation, and management, of this uncommon but challenging thyroid cancer presentation. Expert commentary: Vascular invasion by thyroid cancer is uncommon and has a poor prognosis with high associated perioperative morbidity and mortality. When possible, surgery represents the best management strategy for thyroid cancer exhibiting MVI. In these cases, careful preoperative workup and surgical planning are required in order to balance the goals of maximizing cancer resection while minimizing perioperative mortality and morbidity. Future research should evaluate long-term outcomes following definitive treatment of locally advanced thyroid cancer exhibiting MVI.

KEYWORDS:

Major vessel invasion; extrathyroidal extension; superior vena cava syndrome; thyroid cancer

PMID:
 
30580637
 
DOI:
 
10.1080/14737140.2019.1559059

Adjuvant FOLFIRINOX Pancreatic Cancer

Adjuvant FOLFIRINOX Gives Big Boost to Pancreatic Ca Survival
https://www.medpagetoday.com/hematologyoncology/othercancers/77016

Dec 19th, 2018 - Patients with pancreatic cancer who underwent adjuvantchemotherapy with modified FOLFIRINOX had a median 20-month overall survival (OS) improvement compared with those treated with gemcitabine, results of the PRODIGE 24 trial found. The improvement of median OS from 35.0 months with gemcitabine to 54.4 months with FOLFIRINOX represents a 36% reduction in the ...

Adjuvant modified FOLFIRINOX improves survival of pancreaticcancer
https://www.mdedge.com/oncologypractice/article/191549/gastroenterology/adjuvant-modified-folfirinox-improves-survival
Neil Osterweil, Oncology Practice

Dec 19th, 2018 - For patients with completely or near-completely resected pancreaticductal adenocarcinoma, adjuvant therapy with a modified FOLFIRINOX regimen was associated with significantly better 3-year disease-free survival and overall survival compared with gemcitabine, results of the phase 3 randomized PRODIGE 24 trial showed. At a median follow-up of 33.

Sorafenib Desmoid Tumors

Sorafenib for Advanced and Refractory Desmoid Tumors.Preview
https://www.ncbi.nlm.nih.gov/pubmed/30575484
The New England Journal of Medicine; Gounder MM, Mahoney MR et. al.

Dec 21st, 2018 - Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs. There is no standard of care. In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors...

Sorafenib extends PFS for refractory desmoid tumors
https://www.mdedge.com/oncologypractice/article/191511/rare-diseases/sorafenib-extends-pfs-refractory-desmoid-tumors
Neil Osterweil, Oncology Practice

Dec 19th, 2018 - For patients with progressive, refractory, or symptomatic desmoidtumors – also known as aggressive fibromatosis – treatment with daily sorafenib(Nexavar) was associated with durable responses and a significant improvement in progression-free survival. After a median follow-up of 27.

Sorafenib 'New Standard of Care' for Patients With DesmoidTumors
https://www.medpagetoday.com/hematologyoncology/othercancers/77032

Dec 19th, 2018 - Treatment with sorafenib (Nexavar) induced durable responses and doubled the rate of progression-free survival (PFS) at 2 years in patients with advanced or refractory desmoid tumors, results of a double-blind phase III trial found. Among 84 evaluable patients with symptomatic, progressive, or refractory tumors, the estimated 2-year PFS rate was 81% in the sorafen...

Sorafenib Doubles PFS at 2 Years in Patients With DesmoidTumors for 'New Standard of Care'
https://www.medpagetoday.com/hematologyoncology/othercancers/77101

Dec 21st, 2018 - Action Points In this double-blind, randomized, placebo-controlled Phase III trial of sorafenib (Nexavar) in patients with advanced desmoid tumors, the 2-year progression-free survival rate at 27.2 months was 81% vs 36% for placebo. There is currently no accepted standard of care for desmoid tumors, so the results from this trial with sorafenib may lead...

Sorafenib Prolongs Progression-free Survival in Patients WithDesmoid Tumors
https://www.medscape.com/viewarticle/897781

Jun 8th, 2018 - NEW YORK (Reuters Health) - Sorafenib boosts progression-free survival among patients with desmoid tumors, according to results of a new phase 3 trial. "Sorafenib now represents a very reasonable choice for first-line therapy for patients with desmoid tumors," said Dr. Gary Schwartz of Columbia University School of Medicine in New York, the study's seni...

HER2- Ki67 GSTP1 Genes breast cancer

Combined Detection of HER2Ki67, and GSTP1 Genes on the Di...Preview
https://www.ncbi.nlm.nih.gov/pubmed/30585764
Cancer Biotherapy & Radiopharmaceuticals; Song B, Wang L et. al.

Dec 26th, 2018 - Breast cancer (BC) is a common malignant tumor in females. The combined assay of multiple molecular markers benefits the diagnosis and prognostic prediction. Human epidermal growth factor receptor 2 (HER2) facilitates the proliferation and differentiation of cancer cells through ligand binding. Ki67 is a tumor proliferation-related gene, whereas GSTP1 i...

Association of GSTP1 methylation with aggressive phenotype in ER-positive bre... Preview
https://www.ncbi.nlm.nih.gov/pubmed/24324107
Anticancer Research; Miyake T, Nakayama T et. al.

Dec 11th, 2013 - We investigated the association of glutathione S-transferase P1 (GSTP1) expression and methylation status with clinicopathological characteristics of estrogen receptor (ER)-positive breast cancers. Primary ER-positive breast cancerpatients (n=177, stage I-III) were retrospectively analyzed. A quantitative GSTP1methylation assay was performed using DNA...

Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subg... Preview
https://www.ncbi.nlm.nih.gov/pubmed/23135572
Breast Cancer Research and Treatment; Milde-Langosch K, Karn T et. al.

Nov 9th, 2012 - High proliferation rates are characteristic of cancer, and proliferation markers make up the majority of genes included in RNA-based prognostic gene signatures applied for breast cancer patients. Based on prior data on differences in molecular subgroups of breast cancer, we hypothesized that the significance of single proliferation markers might differ ...

Genomic hotspots but few recurrent fusion genes in breastcancerPreview
https://www.ncbi.nlm.nih.gov/pubmed/29436103
Genes, Chromosomes & Cancer; Fimereli D, Fumagalli D et. al.

Feb 13th, 2018 - The advent of next generation sequencing technologies has boosted the interest in exploring the role of fusion genes in the development and progression of solid tumors. In breast cancer, most of the detected gene fusions seem to be "passenger" events while the presence of recurrent and driver fusions is still under study. We performed RNA sequencing in 55 well-characterized...

Investigation of prognostic value of polymorphisms within estrogen metabolizing gene... Preview
https://www.ncbi.nlm.nih.gov/pubmed/25648141
BMC Medical Genetics; Savukaitytė A, Ugenskienė R et. al.

Feb 5th, 2015 - Breast cancer is the most frequent oncological disease among women. Estrogens are known to play an important role in breast cancer development. Recognition of the relationship between polymorphisms within estrogen metabolizing genes and conventional prognostic factors of breast cancer might improve our knowledge on individualized breast

Levels of uPA and PAI-1 in breast cancer and its correlation toKi67... Preview
https://www.ncbi.nlm.nih.gov/pubmed/30170623
Diagnostic Pathology; Völker HU, Weigel M et. al.

Aug 31st, 2018 - Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more ag...

Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-rel... Preview
https://www.ncbi.nlm.nih.gov/pubmed/18485221
Breast Cancer Research : BCR; Sunami E, Shinozaki M et. al.

May 20th, 2008 - Estrogen receptor (ER)-positive breast cancers are considered prognostically more favorable than ER-negative tumors, whereas human epidermal growth factor receptor (HER)2/neu-positive breast cancers are associated with worse prognosis. The objective of the present study was to determine whether ER-positive and ER-negative status relates to epigenetic changes in br...

Methylated APC and GSTP1 genes in serum DNA correlate with the presence o... Preview
https://www.ncbi.nlm.nih.gov/pubmed/20696638
European Journal of Medical Research; Matuschek C, Bölke E et. al.

Aug 11th, 2010 - Tumor-related methylated DNA and circulating tumor cells (CTC) in the peripheral blood might be of prognostic importance in breast cancer. Thus, the aim of our study was to examine free methylated DNA and CTC in the blood from breast cancer patients and to correlate it with clinicopathological features known to influence prognosis. We prospectively obtained serum sam...

Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Can... Preview
https://www.ncbi.nlm.nih.gov/pubmed/29540052
Cancer Research and Treatment : Official Journal of Korean Cancer Association; Deng L, Zhu X et. al.

Mar 15th, 2018 - The prevalence of PIK3CA in Chinese breast cancer patients may be underestimated. Therefore, we investigated the distribution of somatic PIK3CA/AKT1 mutations in Chinese breast cancer patients and explored their roles in tumor phenotypes and disease prognosis. Tumors from five hundred and seven breastcancer patients were prospectively collected from th...

MicroRNA signatures in hereditary breast cancerPreview
https://www.ncbi.nlm.nih.gov/pubmed/24129975
Breast Cancer Research and Treatment; Murria Estal R, Palanca Suela S et. al.

Oct 17th, 2013 - This study aims to identify signatures of miR associated with hereditary, BRCA1 or BRCA2 mutation positive breast cancer (BC), and non-hereditary BC, either sporadic (SBC) or non-informative (BRCAX). Moreover, we search for signatures associated with tumor stage, immunohistochemistry and tumor molecular profile. Twenty formalin fixed paraffin embedded (FFPE) BCs, BRCA1, BRCA2, BRC...

C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression... Preview
https://www.ncbi.nlm.nih.gov/pubmed/25370037
European Journal of Human Genetics : EJHG; Yamamoto-Ibusuki M, Yamamoto Y et. al.

Nov 6th, 2014 - Genome-wide association studies have identified a single-nucleotide polymorphism (SNP) to be associated with an increased risk of breast cancer. The biology of one of the susceptibility locus C6ORF-ESR1 and whether it also contributes to progression of established disease has not yet been ascertained. We examined the association of rs2046210 and its six linkage disequilibrium SNPs...

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letro... Preview
https://www.ncbi.nlm.nih.gov/pubmed/29718092
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Hortobagyi GN, Stemmer SM et. al.

Apr 27th, 2018 - The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here we report updated efficacy and sa...

Chemoimmunotherapy for Triple-Negative Breast Cancer

Chemoimmunotherapy for Triple-Negative Breast Cancer.Preview
https://www.ncbi.nlm.nih.gov/pubmed/30575878
JAMA Slomski A

Dec 21st, 2018 - Chemoimmunotherapy for Triple-Negative Breast Cancer.|2018|Slomski A,|

Advances in risk assessment and prophylaxis for central nervous system relapse in diffu... Preview
https://www.ncbi.nlm.nih.gov/pubmed/30573511
Haematologica Qualls D, Abramson JS

Dec 20th, 2018 - Central nervous sytem recurrence of diffuse large B-cell lymphoma is an uncommon but devastating event, making identification of patients at high risk for relapse within the central nervous system essential for clinicians. Modern risk stratification includes both clinical and biologic features. A validated clinical risk model employing the 5 traditional international prognostic index risk facto...

First-Line Ibrutinib Confirmed for CLL. Preview
https://www.ncbi.nlm.nih.gov/pubmed/30530733
Cancer Discovery;

Dec 12th, 2018 - Ibrutinib should be a standard of care for many patients with chronic lymphocytic leukemia, according to results from two phase III trials. The BTK inhibitor, given alone or in combination with rituximab, improved clinical outcomes-including progression-free survival-when compared with chemoimmunotherapy regimens.

Targeted Therapies in CLL: Monotherapy Versus Combination Approaches. Preview
https://www.ncbi.nlm.nih.gov/pubmed/30535947
Current Hematologic Malignancy Reports; Khan M, Siddiqi T

Dec 12th, 2018 - While chemoimmunotherapy has improved outcomes in chronic lymphocytic leukemia (CLL), it is not curative, has significant relapse rates, and is not always well tolerated. Recently, novel targeted therapies have been developed to increase response rates and reduce toxicity, especially in high-risk disease. Current goals of CLL therapies are to produce deep and durable, especially minimal ...

Management of unfit elderly patients with chronic lymphocytic leukemia. Preview
https://www.ncbi.nlm.nih.gov/pubmed/30527922
European Journal of Internal Medicine; Eichhorst B, Hallek M et. al.

Dec 12th, 2018 - Chronic lymphocytic leukemia (CLL) is a disease characterized by an increasing incidence with age reaching 35/100,000 in patients over 85 years. Elderly CLL patients carry several challenges, which have to be considered particularly in advanced stages including a higher risk of infections and individual differences in comorbidities and geriatric syndromes. Although no specific tool for geriatri...

Ibrutinib-rituximab 'new standard of care' in younger CLL patients
https://www.mdedge.com/hematologynews/nhlhub/article/190863/cll/ibrutinib-rituximab-new-standard-care-younger-cll-patients
Neil Osterweil

Dec 11th, 2018 - SAN DIEGO – The combination of ibrutinib and rituximab was associated with a two-thirds reduction in chronic lymphocytic leukemia (CLL) progression, compared with standard chemoimmunotherapy in patients younger than 70 years old, interim results of a phase 3 randomized trial showed. Among 529 patients with previously untreated, symptomatic CLL randomly assigned to ibrutinib-rituximab (IR.

Novel therapies for relapsed/refractory aggressive lymphomas.Preview
https://www.ncbi.nlm.nih.gov/pubmed/30504294
Hematology. American Society of Hematology. Education Program; Cohen JB

Dec 7th, 2018 - Most patients with aggressive non-Hodgkin lymphoma will be cured with initial chemoimmunotherapy; however, most patients with relapsed disease will not be cured and will die as a result of their disease. In these cases, continued treatment with conventional chemotherapy is typically not of benefit and can contribute to significant toxicities and decreased quality of life for patients. Fo...

Where to start? Upfront therapy for follicular lymphoma in 2018.Preview
https://www.ncbi.nlm.nih.gov/pubmed/30504308
Hematology. American Society of Hematology. Education Program; Leonard JP, Nastoupil LJ et. al.

Dec 7th, 2018 - The initial approach to the management of follicular lymphoma (FL) is challenging for patients and physicians. Most FL patients present with minimal symptoms; given the lack of a survival benefit to early treatment in this population, a period of observation without therapy is often appropriate. Once there is disease progression beyond low-tumor-burden criteria or symptoms prompting interventio...

Selecting Frontline Therapy for CLL in 2018. Preview
https://www.ncbi.nlm.nih.gov/pubmed/30504317
Hematology. American Society of Hematology. Education Program; Jain N

Dec 7th, 2018 - The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years. The role of chemoimmunotherapy has declined significantly for patients with CLL. Fludarabine, cyclophosphamide, rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL, especially if IGHV mutated. For older adults, ibrutinib has been shown to...

Relapsed CLL: sequencing, combinations, and novel agents.Preview
https://www.ncbi.nlm.nih.gov/pubmed/30504318
Hematology. American Society of Hematology. Education Program; Brown JR

Dec 7th, 2018 - Although the therapy of chronic lymphocytic leukemia (CLL) has changed rapidly over the last 5 years, the key considerations in selecting a therapy for a previously treated patient with CLL continue to include the nature of the prior therapy and the duration of prior remission to that therapy, the prognostic features of the disease, and the health and comorbidities of the patient in question. F...

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. Preview
https://www.ncbi.nlm.nih.gov/pubmed/30501481
The New England Journal of Medicine; Woyach JA, Ruppert AS et. al.

Dec 7th, 2018 - Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy. Patients 65 years of age or ol...

Older CLL Patients See Better PFS With Ibrutinib
https://www.mdedge.com/fedprac/avaho/article/190538/leukemia-myelodysplasia-transplantation/older-cll-patients-see-better

Dec 6th, 2018 - SAN DIEGO – In the phase 3 Alliance A041202 trial of older patients with previously untreated chronic lymphocytic leukemia (CLL), ibrutinib showed superior progression-free survival (PFS). Results of the trial were reported by Jennifer A.

For Older Patients With CLL, Ibrutinib Beats StandardChemoimmunotherapy
https://www.ashclinicalnews.org/on-location/older-patients-cll-ibrutinib-beats-standard-chemoimmunotherapy/

Dec 4th, 2018 - Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib was superior to standard-of-care chemoimmunotherapy for older patients with chronic lymphocytic leukemia (CLL). Lead author Jennifer A. Woyach, MD, from The Ohio State University Comprehensive Cancer Center in Columbus, presented the findings of the Alliance North American Intergr...

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-C... Preview
https://www.ncbi.nlm.nih.gov/pubmed/30523716
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology;Ennishi D, Jiang A et. al.

Dec 3rd, 2018 - High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression. We analyzed RNA sequencing data from 157 de novo ...

Waldenstrom Macroglobulinemia Clinical Practice Guidelines (2018)
https://www.medscape.com/viewarticle/905623

Nov 30th, 2018 - The guidelines on the diagnosis, treatment, and follow-up of Waldenstrom macroglobulinemia were released on October 1, 2018, by the European Society for Medical Oncology (ESMO).[1] Diagnosis Waldenstrom macroglobulinemia (WM) is diagnosed based on histopathologic confirmation of bone marrow (BM) infiltration by monoclonal lymphoplasmacytic cells and serum monoclonal immunoglobulin M (IgM), conf...

Chemo-Free Regimen Feasible for Indolent Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/76531

Nov 26th, 2018 - More than a third of patients with symptomatic indolent lymphoma required no chemotherapy during more than 10 years of follow-up after initial treatment with rituximab (Rituxan), data from two randomized Scandinavian studies showed. Three-fourths of the patients remained alive at the end of follow-up, including 38% of patients with follicular lymphoma never treated with chemotherapy. The random...

Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites. Preview
https://www.ncbi.nlm.nih.gov/pubmed/30464679
Current Oncology (Toronto, Ont.); Stewart DA, Boudreault JS et. al.

Nov 23rd, 2018 - Non-Hodgkin lymphoma (nhl) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (dlbcl) and follicular lymphoma (fl) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Relative to intravenous (IV) rituximab, a subcutaneous (sc) formulation approved in 2016 has comparable pharmacokinetics, efficacy, and safety, and a grea...

What's Hot at This Year's ASH Meeting?
https://www.medscape.com/viewarticle/905521

Nov 23rd, 2018 - The premier event in hematology is celebrating its diamond anniversary. This will be the 60th annual meeting of the American Society of Hematology (ASH). It will be returning to the city of San Diego, California, and will run from November 30 to December 4. More than 25,000 attendees from 155 countries are expected, and more than 4800 abstracts will be presented, Aaron Gerds, MD, chair of ASH's...

ASH 2018 coming attractions look at the big picture
https://www.mdedge.com/jcomjournal/article/189383/aggressive-lymphomas/ash-2018-coming-attractions-look-big-picture/page/0/1

Nov 21st, 2018 - Among these star attractions are results of a phase 3, randomized study of daratumumab (Darzalex) plus lenalidomide and dexamethasone versus lenalidomide-dexamethasone alone for patients with newly diagnosed multiple myeloma who are ineligible for transplant. The investigators found that adding daratumumab reduced the risk of disease progression or death by close to 50%, supporting the combinat.

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Preview
https://www.ncbi.nlm.nih.gov/pubmed/30460980
British Journal of Haematology; Al-Sawaf O, Bahlo J et. al.

Nov 21st, 2018 - Clinical management of chronic lymphocytic leukaemia (CLL) in patients aged ≥80 years is based on limited evidence due to the lack of published information. Therefore, we analysed CLL patients aged ≥80 years using data from seven phase III clinical trials of the German CLL Study Group. Among 3552 participants, 152 were ≥80 years old at initiation of first-line study treatment. Median age was 82...


Thyroid nodules in children and teenagers


Pediatr Rev. 
Consultation with the specialist: thyroid nodules.
Osipoff JN1, Wilson TA.
Author information
1
Division of Pediatric Endocrinology, Department of Pediatrics, Stony Brook Children's Hospital, State University of New York, Stony Brook, NY, USA.
Abstract
Based on strong research evidence, thyroid nodules in children and teenagers are more likely to be malignant than in adults. Based on strong research evidence, a history of ionizing radiation to the head or neck is an independent risk factor for the development of thyroid malignancies. There is strong research evidence, including a recent meta-analysis, supporting the use of fine-needle aspiration biopsy in the evaluation of all pediatric and adolescent patients presenting with a thyroid nodule. The surgical management and postoperative care of pediatric and adolescent patients who have well-differentiated thyroid carcinomas remains controversial, because the rarity of the disease limits the ability to conduct randomized, prospective research studies. Numerous studies have demonstrated that, despite presenting with more advanced disease, pediatric and adolescent patients with thyroid carcinoma have a higher survival rate than adults. The American Thyroid Association has issued strong evidence-based recommendations for the management of medullary thyroid carcinoma, including RET mutation testing and early prophylactic total thyroidectomy in children with high-risk mutations.

PMID: 22301033 DOI: 10.1542/pir.33-2-75
https://www.ncbi.nlm.nih.gov/pubmed/22301033